An Interleukin 21 Protein (IL21) Mutant and Use Thereof

Abstract

The invention relates to an interleukin-21 protein (IL21) mutant and application thereof. The mutant is with ILE at position 16 and SER at position 70 of the amino acid sequence of the wild-type IL21 both mutating into CYS, and a disulfide bond forming between the two mutated CYSs. The amino acid sequence of the wild-type IL21 is shown in SEQ ID NO.1. The invention also relates to a fusion protein containing the IL21 mutant protein and a use of the IL21 mutant protein or the fusion protein in the preparation of a medicine and, preferably, the medicine regulates or activates immunity or are an anti-tumor medicine. The invention also relates to the use of the IL21 mutant, the IL21/4 mutant or the fusion protein in the preparation of a formulation for promoting the differentiation and proliferation of B cell, the differentiation and proliferation of T cell, the differentiation and proliferation of NK cell.

Dependencies are inferred from the claim text.